EUVIMEDEUVIMED entdecken
Open Access

Robust differentiation of NK cells from MSLN.CAR-IL-15–engineered human iPSCs with enhanced antitumor efficacy against solid tumors

Qun Jiang iD, Weiming Yu, James Ma iD, Mingming Zhao, Jizhong Zou iD, Sameer Mir, Jingli Zhang iD, Ronald N Germain iD, Raffit Hassan iD

Science Advances · 02.05.2025 · 11 (18)

DOI: 10.1126/sciadv.adt9932 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 02.05.2025. Verfasst von Qun Jiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic and GI Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda…. Hauptthemen laut MEDLINE: Killer Cells, Natural, Interleukin-15, Induced Pluripotent Stem Cells, Cell Differentiation. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human induced pluripotent stem cells (iPSCs) offer a promising source for chimeric antigen receptor (CAR)–engineered natural killer (NK) products. However, complex iPSC-NK (iNK) manufacturing challenges clinical use. Here, we identified LiPSC-GR1.1 as a superior iPSC line for iNK production. By engineering LiPSC-GR1.1 with a mesothelin (MSLN)–targeting CAR and interleukin-15 (IL-15), we achieved robust differentiation of iPSCs into mature activated iNK cells with enhanced tumor killing efficacy, superior tumor homing, and vigorous proliferation. Single-cell transcriptomic analysis revealed that transforming growth factor–β (TGF-β)–producing tumor cells up-regulated major histocompatibility complex molecules and down-regulated MSLN post–CAR-IL-15 iNK treatment. Tumor-infiltrating CAR-IL-15 iNK cells exhibited high levels of CAR, IL-15, and NK-activating receptors, negligible checkpoint exhaustion markers, and extremely low levels of NK suppressive factors CISH , TGFBR2 , and BATF , enabling them to sustain activation, metabolic fitness, and effective tumor killing within TGF-β–rich hypoxic tumor microenvironment. Overall, we developed MSLN.CAR-IL-15–engineered GR1.1-iNK therapy with enhanced antitumor efficacy for solid tumor treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalInterleukin-15Induced Pluripotent Stem CellsCell DifferentiationReceptors, Chimeric AntigenNeoplasmsHumansMesothelinMiceAnimalsCell Line, TumorTumor MicroenvironmentImmunotherapy, AdoptiveGPI-Linked ProteinsXenograft Model Antitumor Assays

Substanzen

Interleukin-15Receptors, Chimeric AntigenMesothelinMSLN protein, humanIL15 protein, humanGPI-Linked Proteins

Autor:innen und Institutionen

  • Thoracic and GI Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
  • Lymphocyte Biology Section, Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, USA.
  • Center for Advanced Tissue Imaging, NIAID and NCI, NIH, Bethesda, MD, USA.
  • University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • iPSC Core, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA.

ORCID-Profile: Qun Jiang, James Ma, Jizhong Zou, Jingli Zhang, Ronald N Germain, Raffit Hassan

Zitieren

APA

Jiang, Q., Yu, W., Ma, J., Zhao, M., Zou, J., Mir, S., Zhang, J., Germain, R. N., & Hassan, R. (2025). Robust differentiation of NK cells from MSLN.CAR-IL-15–engineered human iPSCs with enhanced antitumor efficacy against solid tumors. Science Advances, 11(18). https://doi.org/10.1126/sciadv.adt9932

Vancouver

Jiang Q, Yu W, Ma J, Zhao M, Zou J, Mir S, et al. Robust differentiation of NK cells from MSLN.CAR-IL-15–engineered human iPSCs with enhanced antitumor efficacy against solid tumors. Science Advances. 2025;11(18). doi:10.1126/sciadv.adt9932

BibTeX
@article{Jiang2025,
  author = {Jiang, Qun and Yu, Weiming and Ma, James and Zhao, Mingming and Zou, Jizhong and Mir, Sameer and Zhang, Jingli and Germain, Ronald N and Hassan, Raffit},
  title = {Robust differentiation of NK cells from MSLN.CAR-IL-15–engineered human iPSCs with enhanced antitumor efficacy against solid tumors},
  journal = {Science Advances},
  year = {2025},
  volume = {11},
  number = {18},
  doi = {10.1126/sciadv.adt9932}
}
Kostenlos starten →